What does this research mean for the field?

The wide variation in the reported prevalence of druggable genetic alterations in non-small cell lung cancer is driven by a complex interplay of demographic, clinical, and methodological factors. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the spectrum of druggable genetic alterations in non-small cell lung cancer and identify the primary demographic, clinical, and methodological factors driving discrepancies in their reported prevalence.

August 29, 2026Journal of Molecular PathologyOpen Access

Discrepancies in the Molecular Epidemiology of Druggable Genetic Alterations in Non-Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

PPPanagiotis PaliogiannisUniversity of Sassari AZAngelo ZinelluUniversity of Sassari GPGiuseppe PalmieriUniversity of Foggia

Discussion

Member takes

Implication

Narrative review reveals extensive variability in druggable genetic alterations in non-small cell lung cancer, highlighting demographic, clinical, and testing discrepancies.

Key Points

To evaluate the spectrum of druggable genetic alterations in non-small cell lung cancer and identify the primary demographic, clinical, and methodological factors driving discrepancies in their reported prevalence.
Narrative review synthesizing epidemiological and molecular data on druggable genomic alterations across East Asian, European, and North American populations.
Evaluation of demographic and clinical influences, including smoking status, environmental exposures, histology, disease stage, and sex.
Assessment of methodological determinants, such as molecular testing platforms, limit of detection, tissue versus liquid biopsy, gene panel design, and intratumoral heterogeneity.
Reported frequencies of targetable alterations differ substantially by geography and ancestry, with marked variations observed between East Asian and Western cohorts.
Clinical and demographic characteristics, including non-smoking history, adenocarcinoma histology, and sex, significantly influence the observed distribution of specific oncogenic drivers.
Methodological divergence across testing platforms, tissue versus liquid biopsy modalities, assay analytical sensitivity, and panel size accounts for significant inter-study heterogeneity.

Cite This Study

Paliogiannis et al. (2026) studied this question.

synapsesocial.com/papers/6a9299338e5d7d1fc0c10f68 https://doi.org/10.3390/jmp7030031

View Full Paper

Ask AI

Bookmark

Implication

Narrative review reveals extensive variability in druggable genetic alterations in non-small cell lung cancer, highlighting demographic, clinical, and testing discrepancies.

Discrepancies in the Molecular Epidemiology of Druggable Genetic Alterations in Non-Small Cell Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Discrepancies in the Molecular Epidemiology of Druggable Genetic Alterations in Non-Small Cell Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider